Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Metal-Ligand Bonds02:51

Metal-Ligand Bonds

The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Complexation Equilibria: Factors Influencing Stability of Complexes01:09

Complexation Equilibria: Factors Influencing Stability of Complexes

In complexation reactions, metal cations are the electron pair acceptors, and the ligands are the electron pair donors. The stability of the metal complexes depends primarily on the complexing ability of the central metal ion and the nature of the ligands. Generally, the complexing ability of the metal ion depends on the size and charge of the ion. As the metal ion size increases, the stability of the metal complexes decreases, provided that the valency of the metal ion and the ligands remain...
Complexation Equilibria: The Chelate Effect01:19

Complexation Equilibria: The Chelate Effect

In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Modular Post-Polymerization Modification Route to Aminated Polybutadienes for Electrochemical CO<sub>2</sub> Valorization.

Journal of the American Chemical Society·2026
Same author

Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.

Metallomics : integrated biometal science·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

A Correlative X‑ray Bioimaging Triad for Metals in Biomedical Research.

Chemical & biomedical imaging·2026
Same author

In Situ Lipid Interactions of an Anticancer Metal Complex.

Inorganic chemistry·2026
Same author

Indirect Baeyer-Villiger Oxidation of Furfural by In Situ Formed HOBr in an Undivided Electrochemical Cell.

ChemSusChem·2025

Related Experiment Video

Updated: Jul 8, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

New trends for metal complexes with anticancer activity.

Pieter C A Bruijnincx1, Peter J Sadler

  • 1Department of Chemistry, University of Warwick, CV4 7AL Coventry, United Kingdom.

Current Opinion in Chemical Biology
|December 25, 2007
PubMed
Summary
This summary is machine-generated.

Medicinal inorganic chemistry is developing novel metal-based anticancer drugs to overcome cisplatin

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jul 8, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Area of Science:

  • Medicinal Inorganic Chemistry
  • Drug Discovery and Development
  • Cancer Therapeutics

Background:

  • Metal ions offer unique properties for designing new drugs.
  • Cisplatin is a clinically used chemotherapeutic agent for cancer, but its use is limited by toxic side effects.
  • Development of new metal-based anticancer agents with novel mechanisms of action is crucial.

Purpose of the Study:

  • To review recent trends in the development of metal-based anticancer agents.
  • To highlight strategies for improving drug selectivity and reducing toxicity.
  • To explore new approaches beyond the traditional cisplatin paradigm.

Main Methods:

  • Review of current research and literature in medicinal inorganic chemistry.
  • Discussion of strategies including prodrug design for selective delivery and activation.
  • Exploration of new non-covalent interactions with DNA and organometallic complexes.

Main Results:

  • Emerging trends focus on selective delivery and activation of cisplatin-related prodrugs.
  • New agents are exploring non-covalent DNA interactions, moving away from direct DNA damage.
  • A shift towards using metals as scaffolds and developing targeted, cancer cell-specific approaches.

Conclusions:

  • Medicinal inorganic chemistry is advancing metal-based cancer therapeutics.
  • New strategies aim for improved efficacy and reduced side effects.
  • The field is entering an exciting phase with novel organometallic complexes and targeted therapies.